109 related articles for article (PubMed ID: 12704865)
1. [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy].
Yamada Y; Irizuki N; Takayanagi R; Yamamoto K; Sawada Y; Iga T
Yakugaku Zasshi; 2003 Apr; 123(4):255-60. PubMed ID: 12704865
[TBL] [Abstract][Full Text] [Related]
2. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
Mizokawa T; Akai T; Nakada Y; Yamaguchi M; Nakagawa H; Hasan S; Rettig KJ; Wachtel H
Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
[TBL] [Abstract][Full Text] [Related]
3. Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.
Platt DM; Rodefer JS; Rowlett JK; Spealman RD
Psychopharmacology (Berl); 2003 Mar; 166(3):298-305. PubMed ID: 12589523
[TBL] [Abstract][Full Text] [Related]
4. [Terguride in hyperprolactinemia--experiences with 5 patients].
Wüster C; Scholz A; Schmelzle A; Horowski R; Ziegler R
Klin Wochenschr; 1990 Apr; 68(7):384-7. PubMed ID: 2188044
[TBL] [Abstract][Full Text] [Related]
5. The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.
McDougall SA; Hernandez RM; Reichel CM; Farley CM
Psychopharmacology (Berl); 2005 Apr; 178(4):431-9. PubMed ID: 15765258
[TBL] [Abstract][Full Text] [Related]
6. The dopamine D(2) partial agonist and antagonist terguride decreases heroin self-administration on fixed- and progressive-ratio schedules.
Zhang D; Wang X; Xiang X; Chen H; Zhang J; Su Q; Hao W
Pharmacol Biochem Behav; 2010 Dec; 97(2):222-6. PubMed ID: 20705086
[TBL] [Abstract][Full Text] [Related]
7. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H
Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532
[TBL] [Abstract][Full Text] [Related]
8. The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen.
Wacan JJ; Reichel CM; Farley CM; McDougall SA
Psychopharmacology (Berl); 2006 Mar; 185(1):104-11. PubMed ID: 16447063
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
[TBL] [Abstract][Full Text] [Related]
10. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule.
Izzo E; Orsini C; Koob GF; Pulvirenti L
Pharmacol Biochem Behav; 2001 Apr; 68(4):701-8. PubMed ID: 11526967
[TBL] [Abstract][Full Text] [Related]
11. Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats.
Yoshida ST; Baella SA; Stuebner NM; Crawford CA; McDougall SA
Brain Res; 2006 Feb; 1073-1074():269-75. PubMed ID: 16427034
[TBL] [Abstract][Full Text] [Related]
12. Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
Ciccarelli E; Touzel R; Besser M; Grossman A
Fertil Steril; 1988 Apr; 49(4):589-94. PubMed ID: 3127243
[TBL] [Abstract][Full Text] [Related]
13. Effects of a partial dopamine D2-like agonist on the cocaine-induced behavioral sensitization of preweanling rats.
Sibole JM; Matea PJ; Krall CM; McDougall SA
Pharmacol Biochem Behav; 2003 Aug; 76(1):27-34. PubMed ID: 13679214
[TBL] [Abstract][Full Text] [Related]
14. Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women.
Venturini PL; Horowski R; Valenzano M; Costantini S; Fasce V; Gorlero F; Rainer E; De Cecco L
Eur J Clin Pharmacol; 1986; 30(2):195-7. PubMed ID: 3709645
[TBL] [Abstract][Full Text] [Related]
15. [Effects of terguride, an ergot alkaloid derivative, on the central nervous system: biochemical and behavioral studies].
Ikoma Y; Akai T; Nakata Y; Hara K; Wachtel H; Yamaguchi M
Nihon Yakurigaku Zasshi; 1993 Aug; 102(2):113-29. PubMed ID: 8370555
[TBL] [Abstract][Full Text] [Related]
16. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
17. Management of restless legs syndrome by the partial D2-agonist terguride.
Sonka K; Pretl M; Kranda K
Sleep Med; 2003 Sep; 4(5):455-7. PubMed ID: 14592288
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
[TBL] [Abstract][Full Text] [Related]
19. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Eur J Pharmacol; 2016 Oct; 789():202-214. PubMed ID: 27395799
[TBL] [Abstract][Full Text] [Related]
20. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.
Martignoni E; Horowski R; Liuzzi A; Costa A; Dallabonzana D; Cozzi R; Attanasio R; Rainer E; Nappi G
Clin Neuropharmacol; 1996 Feb; 19(1):72-80. PubMed ID: 8867520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
